MiMedx Group, Inc.   Report issue

For profit Phase 3 Phase 4
Founded: Marietta GA United States (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2012
NCT01659827
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

MiMedx Group, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dehydration (Phase 4)

Fasciitis (Phase 3)

Fasciitis, Plantar (Phase 3)

Kidney Neoplasms (Phase 4)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Tendinopathy (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 7